Screener
Hemab Therapeutics Holdings, Inc. COAG Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $237,366 | $87,974 |
| Marketable securities | 220,094 | 97,511 |
| Prepaid expenses and other current assets | 6,538 | 7,066 |
| Total current assets | 463,998 | 192,551 |
| Property and equipment, net | 596 | 609 |
| Operating right-of-use assets | 901 | 1,092 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s short-term investments?
- Hemab Therapeutics Holdings, Inc. (COAG) reported short-term investments of $220.09M in Q2 2026.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude